GlassScriptPhysician profile
Melinda Jackson
NPI 1558332734
$2,244.64
in general payments reported to CMS, 2019-2025
22 companies · $714 in 2025
The $714 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $38.17 · 2021: $216 · 2022: $243 · 2023: $286 · 2024: $583 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,582.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,135.79 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $162.74 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $150.69 | 2022-2025 | |
| Lilly USA, LLC | $116.63 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Amarin Pharma, INC. | $112.10 | 2019 | |
| Amgen INC. | $94.43 | 2024-2025 | Otezla, Repatha, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $71.53 | 2024-2025 | Trintellix |
| Glaxosmithkline, LLC. | $56.00 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.16 | 2023-2024 | Jardiance |
| Exact Sciences Corporation | $43.15 | 2024-2025 | Cologuard Collection Kit |
| Allergan, INC. | $34.68 | 2019-2020 | |
| Corium, LLC | $31.32 | 2025 | Azstarys |
| Lundbeck LLC | $28.62 | 2022-2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $25.93 | 2021 | |
| Amneal Pharmaceuticals LLC | $24.77 | 2024 | Unithroid |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $17.94 | 2022 | |
| Esperion Therapeutics, INC. | $16.69 | 2025 | Nexletol |
| Inspire Medical Systems, INC. | $16.38 | 2025 | Inspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.40 | 2025 | Xifaxan |
| Shire North American Group INC | $13.54 | 2019 | |
| Phathom Pharmaceuticals, INC. | $13.04 | 2025 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $12.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melinda Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.